Verubulin
Alternative Names: Azixa; EP-90745; MPC-6827; MX-128495; VeribulinLatest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator EpiCept Corporation
- Developer Immune Pharmaceuticals Inc; Myrexis
- Class Antineoplastics; Quinazolines; Small molecules
- Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Brain metastases; Glioblastoma; Malignant melanoma
- No development reported Neurodegenerative disorders; Solid tumours
- Discontinued Colorectal cancer
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-0 development in Neurodegenerative-disorders in USA (IV)
- 28 Dec 2024 No recent reports of development identified for phase-0 development in Neurodegenerative-disorders(In volunteers) in USA (IV)
- 27 Dec 2022 Phase-0 development for Neurodegenerative disorders is ongoing in USA (IV) (NCT04575727)